U.S. Markets closed

Here’s What’s Moving Amarin Corporation and Puma Biotechnology

Mark Collins

Amarin Corporation plc (NASDAQ:AMRN) and Puma Biotechnology, Inc. (NASDAQ:PBYI) both updated markets as to the progress of their respective lead development programs early this week and both fresh inputs have translated to movement in the companies’ share prices.

Here’s what happened.

Amarin

Amarin is trying to get an asset called Vascepa to market in the US as a treatment for hypertriglyceridemia, or high levels of triglycerides in the blood. The drug is already approved in a similar indication, with the FDA having green-lighted the asset back in 2012 for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia. That’s the severe end of the spectrum, however, which limits the potential market quite considerably.

The current program is designed to show that Vascepa, when combined with statin therapy, will be superior to statin therapy alone when used as a preventative for reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia. Dyslipidemia simply refers to an abnormal amount of lipids (triglycerides, cholesterol and/or fat phospholipids) in the blood.

Statins are currently the standard of care therapy in this indication and are prescribed second only to diet and exercise when a patient is diagnosed with the condition. As many as 33% of the US population suffers from high cholesterol, triglycerides, or both, with estimates suggesting that up 56 million Americans ages 40 to 75 are eligible to for statin therapy. Around 25 million are already taking statins.

If Amarin is able to prove that its drug can improve on the current statin treatment, there’s a very large potential market waiting for the drug when it hits shelves. One of the largest in the US, in fact.

And that’s what the latest trial is set up to do. The company wanted to show that the drug, when combined with statins in this patient population, can reduce cardiovascular events like heart attack and stroke compared to those patients that just receive statin treatment alone.

The latest update detailed that more than 90% of the targeted 1,612 primary major adverse cardiovascular events (MACE) have been reported and that patients are being scheduled for final study visits commencing March 1, 2018. Further, the company maintained previous guidance that top-line data will hit press before the end of 3Q 2018.

On the back of Amarin confirming that it’s on track for a timely report, the stock has gained about 10%. If data prove positive, it could gain much more.

Puma Biotechnology

Puma just announced the outcome of a meeting of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which was set up to discuss and review the company’s Marketing Authorization Application (MAA) for the drug neratinib. The company is trying to get neratinib approved in Europe as an extended adjuvant treatment for patients with early-stage HER2-positive breast cancer.

As per the latest report, the application’s chances of picking up approval do not look good.

The CHMP pointed to the fact that the study results rest on evidence from a single pivotal trial and, additionally, that 2- and 5-year invasive disease free survival (iDFS) benefits observed to-date “may lack sufficient clinical relevance.”

This is a real setback for Puma, given that a large part of the company’s current valuation rests on this asset picking up approval in Europe.

There’s a vote scheduled for mid-February this year, as part of which the CHMP will formalize its review of the application and submit the review to the EMA ahead of the latter’s decision.

Markets are anticipating that the formal vote isn’t going to be any more favorable than the latest panel outcome and trading down on the company as a result.

At the close of trade on Tuesday, Puma was trading for a 4% discount to its daily open and, ahead of the open on Wednesday, pre-market trading has extended this decline by a further 29%.

Chances are we’ll see a continuation of this decline as normal participation gets underway on Wednesday in the US.

If you enjoyed this article, read this next: Celgene, Novartis Both Report Billion Dollar Buyouts

The post Here’s What’s Moving Amarin Corporation and Puma Biotechnology appeared first on Market Exclusive.

  • Business
    TheStreet.com

    Why Auto Parts Stocks Are Getting Hammered

    The overall stock market is about flat on the day but these names are far from it. AutoZone, though, is about flat on the year. and Advance Auto are teaming up for a speciality online auto-parts store.

  • A former GE exec who trained new managers found that almost all of them were making the same mistake
    Business
    Business Insider

    A former GE exec who trained new managers found that almost all of them were making the same mistake

    Beth Comstock is the former vice chair of General Electric. Comstock would hand out "permission slips" authorizing employees to take risks — but she also said it's important for people to stop hiding behind their excuses. Beth Comstock doesn't tolerate excuses.

  • Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'
    Business
    Yahoo Finance

    Ken Langone: 'Who the hell in their right frame of mind would be buying bonds now?'

    Billionaire investor and philanthropist Ken Langone, the founder of The Home Depot (HD) and chairman of Invemed Associates, argued that there’s some “big time” structural problems in the market right now. Because if we are on a trajectory of raising rates that means, and if it keeps going that way and I don’t know how high it will go, and it keeps going that way then all the sudden the guy who bought those bonds is going to be looking at a fairly decent loss,” Langone said.

  • Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect
    Business
    Zacks

    Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect

    Sarepta Therapeutics (SRPT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 24.

  • Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade
    Finance
    Market Realist

    Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade

    Home Depot Stock Falls 4.5% on Credit Suisse’s Downgrade Credit Suisse’s downgrade Today, CNBC reported that Credit Suisse downgraded Home Depot (HD) stock from “outperform” to “neutral.” Credit Suisse lowered its price target from $222.00 to $204.00

  • Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves
    News
    MarketWatch

    Netflix is ditching freeloaders from subscriber forecasts after volatile stock moves

    After two consecutive off-the-mark quarters, falling short of its own forecasts for subscriber growth, Netflix Inc. hopes to put an end to the big swings in its stock price with some changes to its accounting. Three months ago, Netflix reported weaker-than-expected subscriber growth, sending its stock tumbling about 12% in the next trading day. From last quarter: Is Netflix stock falling down a mountain, or just tripping over a molehill?

  • Business
    Barrons.com

    Starbucks Stock Is Getting Analysts Excited Again. Here’s Why

    Activist investor Bill Ackman sees an opportunity, having recently announced a stake in Starbucks (SBUX). Meanwhile, several analysts have recently backed the stock. Herzog believes that the company’s delivery partnership with Alibaba (BABA) should help as Starbucks continues to expand in China and thinks product innovation and digital initiatives, as well as store-level improvements, can energize U.S. sales.

  • Housing Stocks Tumble Midday; Home Depot Dents Dow
    Finance
    Investing.com

    Housing Stocks Tumble Midday; Home Depot Dents Dow

    Investing.com - Home Depot (NYSE:HD) and other housing-leveraged stocks fell in midday trading following disappointing data on home construction. Home Depot fell about 4.2% at 12:08 PM ET (16:08 GMT) and was a drag on the Dow Jones Industrial Average

  • Could Enbridge Inc. Be a Millionaire-Maker Stock?
    Finance
    Motley Fool

    Could Enbridge Inc. Be a Millionaire-Maker Stock?

    Enbridge (NYSE: ENB) has made its investors lots of money over the years. To put that into perspective, if an investor had bought $10,000 worth of Enbridge's stock 20 years ago, it would be worth about $116,000 today assuming they reinvested their dividends. While Enbridge has done an excellent job creating wealth for investors in the past, it faces an uphill battle in making them millionaires in the future.

  • STOCKS on the move: Netflix, Facebook, McDonald's, J&J, Home Depot, IBM
    Business
    Yahoo Finance Video

    STOCKS on the move: Netflix, Facebook, McDonald's, J&J, Home Depot, IBM

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves.

  • Here's the Average Social Security Benefit for 2019
    Business
    Motley Fool

    Here's the Average Social Security Benefit for 2019

    Millions of seniors collect Social Security, and without it, they'd be underwater on their bills. At present, the average retiree gets $1,422 a month in Social Security benefits. There's a world of misinformation surrounding Social Security, and perhaps one of the most detrimental myths out there is the notion that the program is enough to sustain seniors by itself.

  • Sears soars 36% — one day after filing for bankruptcy (SHLD)
    Business
    Business Insider

    Sears soars 36% — one day after filing for bankruptcy (SHLD)

    The retailer received approval on Tuesday to access a $300 million loan to keep it afloat during bankruptcy. Sears Holdings soared as much as 124% — one day after filing for bankruptcy — as the embattled retailer received approval to access a $300 million loan to keep it afloat during bankruptcy.

  • Business
    CNBC

    Berkshire Hathaway shares look really cheap using Warren Buffett's own method of valuing stocks

    Companies pay investors dividends but they also retain some of their earnings. Over time, companies invest these retained earnings at a higher rate of return and that ultimately boosts their share prices, benefiting their investors. J.P. Morgan analyst Sarah DeWitt calculates that Berkshire's share of undistributed earnings from its stock portfolio is $12 billion, or about $5.19 per Berkshire Class B share.

  • IBM disappoints, more Facebook accusations, Apple apologizes
    Finance
    Yahoo Finance

    IBM disappoints, more Facebook accusations, Apple apologizes

    Here’s a look at some of the companies the Yahoo Finance team will be watching for you today. IBM investors aren’t thrilled with the latest earnings report. The company posted a beat on earnings but revenue missed. CEO Ginni Rometty says the results show

  • Skechers to Report Its Q3 2018 Results on September 18
    Finance
    Market Realist

    Skechers to Report Its Q3 2018 Results on September 18

    Can Skechers Hit Its Stride in Q3 2018? Skechers’ Q3 2018 earnings preview Skechers (SKX) is slated to report its third-quarter results after the market closes on October 18. Wall Street expects to see a 14.0% YoY (year-over-year) decline in Skechers

  • Legal pot in Canada putting pressure on US
    CGC
    Yahoo Finance Video

    Legal pot in Canada putting pressure on US

    Canada’s moves to legalize recreational marijuana could have major impacts on the US. Yahoo Finance’s Alexis Christoforous speaks with Alexis Keenan about the state of legalization in this country.

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Business
    Motley Fool

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson (NYSE: JNJ) recently kicked off earnings season for the healthcare sector, and big pharma investors expecting stagnating sales were pleasantly surprised. Despite a pledge not to raise drug prices earlier this year, pharmaceutical sales kept on climbing, especially among the company's young oncology lineup. Strong uptake of innovative new cancer therapies bodes well for a couple of J&J's peers.

  • GE to pay penalty if falls short of French job pledges: ministry
    Business
    Reuters

    GE to pay penalty if falls short of French job pledges: ministry

    General Electric's new CEO told France's finance minister on Wednesday that it would stick to his predecessor's French job pledges or pay a penalty, the Finance Ministry said. Former CEO John Flannery warned French Finance Minister Bruno Le Maire in June that the target was "out of reach", and the government raised the possibility of fines worth 50,000 euros ($57,570) for each job not created. GE's new CEO Larry Culp, who took up his post at the start of the month, told Le Maire in a meeting on Wednesday that France remained a strategic country for the company, the ministry said in statement.

  • Better Buy: The Home Depot, Inc. vs. Lowe's
    Business
    Motley Fool

    Better Buy: The Home Depot, Inc. vs. Lowe's

    Home Depot (NYSE: HD) and Lowe's (NYSE: LOW) have helped countless homeowners increase the value of their homes. They've also made many investors rich. With their shares having soared 879% and 484%, respectively, over the past decade, Home Depot and Lowe

  • Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For
    Business
    Zacks

    Advanced Micro Devices (AMD) Q3 Earnings Preview: Here's What to Look Out For

    Advanced Micro Devices (AMD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on October 24, 2018, might help the stock move higher if these key numbers are better than expectations.

  • Business
    Benzinga

    Kinder Morgan's Q3 Earnings Preview

    Kinder Morgan (NYSE: KMI) will be releasing its next round of earnings Wednesday. For all of the relevant information, here is your guide for the Q3 earnings announcement. Earnings and Revenue Analysts expect Kinder Morgan earnings of 21 cents per share

  • AT&T (T) Q3 Earnings Preview: How Are Events Shaping Up?
    Business
    Zacks

    AT&T (T) Q3 Earnings Preview: How Are Events Shaping Up?

    The market expects AT&T (T) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 24.

  • Business
    CNBC

    Walmart saves $200 million by changing its light bulbs and $20 million with a new floor wax

    Walmart says switching to LED lights in its parking lots cut its annual energy costs by $200 million. A change in the floor wax it uses cut costs by $20 million a year because the floors need to be buffed less often. It's exactly what Walmart WMT is doing.

  • A Look at AT&T’s Dividends
    Finance
    Market Realist

    A Look at AT&T’s Dividends

    What Investors Should Know about AT&T’s Growth Prospects (Continued from Prior Part) Shareholder returns Increasing capital returns to shareholders is one of AT&T’s (T) main priorities. In the second quarter, the company returned $3.1 billion to shareholders

  • Kinder Morgan Canada's profit surges on TransMountain sale
    Business
    Reuters

    Kinder Morgan Canada's profit surges on TransMountain sale

    The company said on Wednesday it expects to return about C$1.2 billion ($921.5 million) or C$11.40 per restricted voting share from the sale to its shareholders. Its parent, U.S.-based Kinder Morgan Inc, closed the sale of the controversial Trans Mountain pipeline to the Canadian government for C$4.5 billion in August. Kinder Morgan Canada said net income rose to C$1.35 billion in the three months ended Sept. 30, from C$42.4 million, a year earlier.